Stability of a less-painful intravenous emulsion of clarithromycin

Add time:08/16/2019    Source:sciencedirect.com

The chemical stability of a less-painful ready-to-use o/w emulsion for intravenous (i.v.) delivery of clarithromycin was investigated. The formulation contained 0.5% w/v drug, 2% w/v soybean oil, 5% w/v egg phosphatide, 0.6% w/v oleic acid, 0.3% hexanoic acid and 2.5% w/v glycerin in water. The change in the initial pH of emulsion (range: 6.5–8.0) did not significantly influence drug stability over a period of 30 days at 5 and 30°C. The increase in the initial pH of emulsion as well as its storage temperature gradually decreased the final pH over time. The emulsion prepared at pH 7.5 demonstrated a constant drop in pH over 9 months at 30°C at the rate of about 0.002 units drop in pH per day; however, it did not demonstrate significant loss of drug. Actual as well as projections using accelerated stability studies indicated the shelf-life (i.e., time to retain 90% of the label claim, t90%) of the emulsion formulation, at 25°C, to be ≥ 21 months. Overall, the results suggest that the development of a less-painful ready-to-use o/w emulsion of clarithromycin is feasible.

We also recommend Trading Suppliers and Manufacturers of CLARITHROMYCIN LACTOBIONATE (cas 135326-55-5). Pls Click Website Link as below: cas 135326-55-5 suppliers

Prev:Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers
Next:Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization)